RASSF1A, a major member of the RASSF1 gene family, is silenced by promoter methylation at a high frequency in a large number of human solid tumors. Controlled expression of RASSF1A reverts the tumorigenic phenotype of several human cancer cell lines. Here we investigated another main isoform, RASSF1C, and compared it with RASSF1A in the gene inactivation test (GIT), based on a tetracycline regulation system. In the small-cell lung cancer (SCLC) line U2020, only RASS-F1A has shown growth inhibitory activity in vitro, while in the prostate cell line LNCaP and renal cell carcinoma (RCC) line KRC/Y both RASSF1A and RASSF1C showed similar (approximately 90%) suppressing activity in vitro. Both RASSF1C and RASSF1A suppressed the tumorigenicity of the KRC/Y RCC cell line in SCID mice. Mutations, deletions and loss of expression of RASSF1A and RASSF1C transgenes were identified in all 15 grown SCID tumors. In contrast, the mutant RASSF1A containing Cys65Arg and Val211Ala had reduced growth suppression activity both in vitro and in vivo and did not show any further changes in four grown SCID tumors. In addition, RASSF1C was shown to induce cell cycle arrest in KRC/Y cells. These results strongly imply that like RASSF1A the RASSF1C gene could serve a tumor suppressor function.
RASSF1A, a major member of the RASSF1 gene family, is silenced by promoter methylation at a high frequency in a large number of human solid tumors. Controlled expression of RASSF1A reverts the tumorigenic phenotype of several human cancer cell lines. Here we investigated another main isoform, RASSF1C, and compared it with RASSF1A in the gene inactivation test (GIT), based on a tetracycline regulation system. In the small-cell lung cancer (SCLC) line U2020, only RASS-F1A has shown growth inhibitory activity in vitro, while in the prostate cell line LNCaP and renal cell carcinoma (RCC) line KRC/Y both RASSF1A and RASSF1C showed similar (approximately 90%) suppressing activity in vitro. Both RASSF1C and RASSF1A suppressed the tumorigenicity of the KRC/Y RCC cell line in SCID mice. Mutations, deletions and loss of expression of RASSF1A and RASSF1C transgenes were identified in all 15 grown SCID tumors. In contrast, the mutant RASSF1A containing Cys65Arg and Val211Ala had reduced growth suppression activity both in vitro and in vivo and did not show any further changes in four grown SCID tumors. In addition, RASSF1C was shown to induce cell cycle arrest in KRC/Y cells. These results strongly imply that like RASSF1A the RASSF1C gene could serve a tumor suppressor function.
Introduction
Loss of genetic material of human chromosome 3p21.3 is one of the most common and earliest events in the pathogenesis of lung, breast, ovarian, nasopharyngeal, renal carcinomas and many other solid tumors. Homozygous deletions at 3p21.3 have been described in several cancer cell lines and in primary lung, cervical and other tumors (see Kok et al., 1997; Zabarovsky et al., 2002; Senchenko et al., 2003 Senchenko et al., , 2004 .
We subdivided 3p21.3 into centromeric 3p21.3C, LUCA and telomeric (3p21.3T, AP20) subregions and discovered frequent homozygous deletions (10-18%) in both. This strongly suggests that the region harbors multiple, probably synergistically acting, tumor suppressor genes (TSG) that are involved in the origin, or development, of major human malignancies (Wei et al., 1996; Alimov et al., 2000; Lerman et al., 2000; Zabarovsky et al., 2002; Protopopov et al., 2003; Senchenko et al., 2003 Senchenko et al., , 2004 .
Originally, in the LUCA locus, the targeted region was narrowed down to a 120 kb region, using three lung and one breast cancer cell line (Sekido et al., 1998) , and this region contains eight candidate TSG (Lerman et al., 2000) . However, subsequent mapping of an additional 15 homozygous deletions revealed a larger minimal homozygously deleted region of about 320 kb that included the previously isolated and analysed 17 genes, from centromeric CACNA2D2 to telomeric SEMA3F (Senchenko et al., 2003 (Senchenko et al., , 2004 . Moreover, it was also shown that the SEMA3B and SEMA3F genes, located outside the 120 kb region, possessed strong growth suppressing features (Tomizawa et al., 2001; Tse et al., 2002; Xiang et al., 2002) . Therefore, it is likely that the larger, 320 kb deletion region, harbors several TSG.
RASSF1, a new putative RAS effector gene, is one of the genes located in the LUCA region. Two major splice forms of RASSF1, RASSF1A and RASSF1C are expressed from two different promoter regions, and they have in common their last four exons (Figure 1 ), which encode a putative RAS association (RA) domain that can be subdivided into RAS binding and RAS core domains (Dammann et al., 2000; Burbee et al., 2001) . RASSF1A (340 amino acids, approximately 2.0 kb mRNA) contains a potential SH3 domain and an amino-terminal cysteine-rich region, which has a high homology to the diacylglycerol/phorbol ester binding domain (DAG binding) found in the protein kinase C family of proteins. RASSF1C (270 amino acids, 1.8 kb mRNA) is a smaller protein and lacks the aminoterminal SH3 and DAG binding domains.
Silencing by methylation of the RASSF1A promoter is a common event in many human cancers. This phenomenon has been reported by us and others in 80-100% of small-cell lung carcinoma (SCLC) cell lines and tumors (Dammann et al., 2000; Burbee et al., 2001) , 30-40% of non-small cell lung cancer (NSCLC) cell lines and tumors (Agathanggelou et al., 2001; Burbee et al., 2001) , 49-62% of breast cancers (Burbee et al., 2001; Dammann et al., 2001) , 35-60% of bladder cancers (Lee et al., 2001; Maruyama et al., 2001) , 67% of primary nasopharyngeal cancers (NPCs) (Lo et al., 2001) , 91% of primary renal cell carcinomas (RCCs) and 100% of RCC cell lines (Dreijerink et al., 2001) , 56-63% of prostate cancer cell lines and tumors (Kuzmin et al., 2002) . Ectopic expression of RASSF1A has growth-suppressing properties when transfected into NSCLC cell lines A549 and H1299 and RCC line (KRC/Y) (Dammann et al., 2000; Burbee et al., 2001; Dreijerink et al., 2001) .
RASSF1C did not show hypermethylation of its promoter region and was expressed in almost all tested lung and breast tumor cell lines and tumors; for instance, 16 of 17 SCLC cell lines expressed RASSF1C (Dammann et al., 2000 ; see also Burbee et al., 2001) . The majority of publications report that RASSF1A, but not RASSF1C, has tumor-suppression activity (Dammann et al., 2000; Burbee et al., 2001; Ji et al., 2002; OrtizVega et al., 2002; Shivakumar et al., 2002 and other) . However, Vos et al. (2000) reported that six of nine transformed ovarian cell lines had lost the expression of RASSF1C. These findings may indicate that RASSF1C has a tissue-specific effect. Unfortunately, Vos et al. (2000) used a high concentration of proteins in vitro and a vector that mediated strong, noncontrolled, overexpression. These factors could lead to artificial results (Ortiz-Vega et al., 2002) .
In the present study, we compared the growth suppressing abilities of RASSF1A and RASSF1C in SCLC cell line U2020, RCC cell line KRC/Y and prostate cancer cell line LNCaP using a tetracyclineregulated system that permits more careful and reliable functional studies of trangenes than most other test systems based on uncontrolled overexpression of transgenes.
Results
Growth inhibition by RASSF1C and RASSF1A in vitro As mentioned above, RASSF1C is expressed in a majority of lung and breast cancer cell lines (Dammann et al., 2000; Lerman et al., 2000; Burbee et al., 2001) . However, the expression of RASSF1C was almost undetectable in the KRC/Y RCC cell line, which was used in our growth suppression experiments testing the activity of RASSF1A (Dreijerink et al., 2001) .
RASSF1C was cloned into a pETE (Elimination Test Episomal) tetracycline-regulated vector and used for transfection of the KRC/Y cells (colony formation experiments, anchorage-dependent growth). Original empty pETE vector was used as a negative control, while the pETE with the RASSF1A insert served as a positive control. Figure 2 shows that RASSF1C has a strong growth inhibition effect. The number of colonies formed with expressed RASSF1A and RASSF1C was 10 and 9%, respectively, as compared to control empty vector transfections (Figure 2a) .
We investigated RASSF1C and RASSF1A using the gene inactivation test (GIT) as described by Li et al. (1999) and Protopopov et al. (2002) . The test is based on the functional inactivation of the analysed transgenes. Our hypothesis was that TSG must be inactivated in growing tumors in experimental conditions, similarly to natural tumors.
We used an episomal tetracycline-regulated pETEHyg vector and cells constitutively producing tTA tetracycline trans-activator. Clonal cell lines were selected that expressed transgenes in a tetracycline controlled manner. These clones were introduced into SCID mice and the expression of the transgenes was controlled by tetracycline administered ad libitum in the drinking water. Under selection pressure in vivo tumor cells may eliminate or mutate the expressing transgenes and develop tumors. These delayed tumors were then analysed for the elimination of functional transgenes (Li et al., 1999) .
Two cancer cell lines constitutively producing tTA tetracycline trans-activator were chosen for the experiments: the SCLC cell line U2020, carrying a homozygous deletion of the RASSF1 locus (data not shown), Gene inactivation test with the RASSF1A and RASSF1C J Li et al and the RCC cell line KRC/Y, with low or no expression of these RASSF1 genes. In these experiments pETE-mutRASSF1A, containing a double-mutant RASSF1A (Cys65Arg and Val211Ala), was also used in addition to pETE-RASSF1C and pETE-RASSF1A, bearing wild-type alleles of the tested genes. These constructs were transfected into U2020 and KRC/Y and expression of the transgenes was tested by Northern hybridization. The best tetracycline-regulated clones were then used in further experiments (see for example Figure 3 ).
Growth inhibition experiments with U2020 transfected with pETE, pETE-RASSF1C, pETE-RASSF1A and pETE-mutRASSF1A gave the same results as had been published with NSCLC lines. The pETE-RASS-F1A showed strong growth inhibition (75% suppression on day 5); however, cells containing empty pETE, pETE-RASSF1C and pETE-mutRASSF1A grew with approximately the same rate (data not shown).
A similar experiment was carried out with RASSF1A/ KRC/Y clone1 (RA1), mutant RASSF1A/KRC/Y clone1 (mRA1) and RASSF1C/KRC/Y clone1 (RC1). Figure 4a shows the results. In contrast to cells with the mutRASSF1A, both RASSF1A and RASSF1C drastically suppressed cell growth in the absence of doxycycline (87-89% suppression on day 7 and 92% on day 12). Clones with mutant RASSF1A (mRA1) showed much less growth inhibition.
Some growth retardation was observed in the presence of doxycycline. The most probable reasons for it are expression leakage of transgenes and the inhibitory effect of doxycycline itself (Rubins et al., 2001) .
We have previously shown that RASSF1A strongly inhibited growth of prostate cancer cell line LNCaP (Kuzmin et al., 2002) . Therefore, we repeated the experiments with LNCaP using all above constructs. Again, strong growth suppression was observed with both RASSF1A and RASSF1C but not with mutRASS-F1A (Figure 4b ).
GIT with RASSF1A and RASSF1C in SCID mice KRC/Y derived RASSF1A (six mice/RA1 and two mice/ RA14) and RASSF1C (six mice/RC1 and two mice/ RC5) cell clones were inoculated into 16 SCID mice; mutant RASSF1A mRA1 clone was inoculated into four mice (Table 1) were inoculated. In control mice, empty pETE vector transfected KRC/Y cells were used. Half of the SCID mice were then given drinking water containing 1 mg/ml tetracycline. Results of these experiments are shown in Figure 5 . In one case when RC1 cells with RASSF1C were inoculated, no growth was observed at all. Strong inhibition of tumor growth was observed for all four RASSF1A and RASSF1C clones. The difference in the tet þ and tetÀ tumor growth rate was less pronounced than in in vitro experiments. It is known that tetracycline is a weaker inhibitor of expression compared to doxycycline in the tTA system, and it is likely that expression leakage is stronger in vivo in SCID mice than in vitro. No inhibition of tumor growth with mRA1 clone was detected. All 19 tumors were explanted and tested for the presence of pETE-RASSF1A, pETE-mutRASSF1A and pETE-RASSF1C constructs by PCR. Transgenes were detected in all 19 tumors, though RASSF1A in two tumors (T9 and T10) and RASSF1C in two tumors (T14 and T15) gave a very weak signal (Table 1) . In tumors derived from RA1, expression of RASSF1A was detected by Northern hybridization in three tumors from SCID mice receiving water without tetracycline (T2, T4 and T6), but not in the tumors from SCID mice receiving water with tetracycline (T1, T3 and T5) (Figure 6 ). Similar results were obtained using tumors grown from RC1 and mRA1 clones.
In all four tumors derived from RA14 and RC5 expression of transgenes was undetectable by Northern hybridization (Figure 6 , Table 1 ), and all expressed transgenes were sequenced. RASSF1A in T2 had one base insertion (1017insG; Accession #AF102770) resulting in a frameshift mutation (CGC CAG AAG to CGC Gene inactivation test with the RASSF1A and RASSF1C J Li et al GCA GAA, ArgGlnLys326 to 328ArgAlaGlu), tumors T4 and T6 contained missense mutations CTG to GTG (Leu268Val) and GAT to GTG, Asp262Tyr, respectively. The RASSF1C in T9 had a missense mutation TCT to TTT (Ser61Phe) and tumor T12 contained a missense mutation also (GTC to GCC, Val212Ala) . No additional mutations of mutRASSF1A gene were identified in two tumors expressing the gene.
RASSF1C induced cell cycle arrest in KRC/Y cells
It was reported that expression of RASSF1A blocks cell cycle progression (Shivakumar et al., 2002) . We examined whether RASSF1C possesses the same function in KRC/Y cells. RC1 cells with and without doxycycline were trypsinized, fixed, and stained with propidium iodide to examine for DNA content by FACS. KRC/Y cells with vector pETE were used as a negative control and the ovarian cell line SKOV expressing wild-type P53 was used as a positive control. Analysis of propidium iodide incorporation showed that wild-type P53 induced apoptosis in SKOV cells as expected. Expressed RASSF1C (without doxycycline) induced cell cycle arrest in KRC/Y cells similar to P53 and nonexpressed RASSF1C (with doxycycline) had no effect on the cell cycle ( Figure 7 ).
Discussion
The main conclusions of this study are the following. In the SCLC line U2020, only RASSF1A has growth inhibitory activity in vitro. In prostate cell line LNCaP and RCC line KRC/Y both RASSF1A and RASSF1C have practically identical suppressor activity in vitro.
The number of KRC/Y colonies formed in anchorage-dependent colony formation experiments with expressed RASSF1A and RASSF1C was 9-10% of that from control cells transfected with the vector. It was reported earlier, by Burbee et al. (2001) , that expression of RASSF1A in H1299 cells resulted in a 40-60% decrease in anchorage-dependent colony formation, and Dammann et al. (2000) reported that RASSF1A had only approximately 30% colony formation efficiency in A549, compared to vector control. Thus in KRC/Y cells, RASSF1C has an even stronger growth inhibition effect than does RASSF1A in NSCLC lines.
Experiments showed also that both RASSF1C and RASSF1A revealed strong suppressor activity in vivo in KRC/Y cells.
We have performed GIT with RASSF1C and RASSF1A and found that in all grown tumors both Gene inactivation test with the RASSF1A and RASSF1C J Li et al genes were inactivated by either loss of expression or mutation. In contrast, the mutant RASSF1A gene was expressed without additional mutations in all tumors derived from inoculation of mRA1 cells. These results are remarkably similar to those from the RB and P53 experiments. In those experiments, the human RB1 gene was transfected and expressed in the mouse A9 fibrosarcoma cell line under tetracycline regulation. Following passage of the RB1 transfectants through SCID mice, the wild type RB1 gene was already deleted or functionally inactivated after the first passage in all 20 tumors tested (Li et al., 1999) . The same results were obtained with the RB1 and P53 genes using KRC/Y as a recipient cell line (Imreh et al., 2003) .
It was reported that RASSF1A could induce cell cycle arrest by engaging the RB cell cycle checkpoint at the level of G1/S-phase cell cycle progression. RASSF1A inhibits accumulation of native cyclin D1, and this inhibition occurs post-transcriptionally and is likely at the level of translational control (Shivakumar et al., 2002) .
It was suggested that RASSF1A associates with Ras-GTP indirectly, through its ability to heterodimerize with a Ras-GTP binding protein, either NORE itself, or another NORE homolog capable of binding both RASSF1A and Ras-GTP (Ortiz-Vega et al., 2002) . Moreover, the same authors reported that RASSF1C was unable to bind Ras-GTP either directly or through heterodimerization with NORE. It was also shown that oncogenic RasG12V expression did not detectably alter RASSF1A's growth inhibitory activity (Shivakumar et al., 2002) in human mammary epithelial cells HME50-hTERT.
RASSF1C did not show the hypermethylation of its promoter region and was expressed in almost all tested tumor cell lines and tumors (Dammann et al., 2000; Burbee et al., 2001; Lerman et al., 2000) . Increasing the levels of RASSF1C protein did not greatly affect the proliferation of some cell types including several epithelium-derived tumor cell lines, normal mammary epithelial cells, NIH 3T3 fibroblasts and HEK293 cells (Ji et al., 2002; Shivakumar et al., 2002) .
In contrast to this observation, Vos et al. (2000) reported that six of nine transformed ovarian cell lines had lost the expression of RASSF1C, and RASSF1C could induce apoptosis when overexpressed in HEK293-T cells and NIH 3T3 cells. RASSF1C loss of expression in ovarian versus lung tumor cell lines could reflect tissue-dependent differences in biological activity of the RASSF1 isoforms (Vos et al., 2000) . Possibly, the absence of the RASSF1A transcript or the ratio of RASSF1A to RASSF1C may be critical for tumorigenesis in this model. Importantly, in our study mutant RASSF1A (Cys65Arg and Val211Ala) had much reduced growth inhibition activity both in vitro and in vivo (see also Dreijerink et al., 2001) . These two mutations are located in two critical functional regions of the RASSF1A protein, the protein kinase C1 homology domain (Cys65Arg) and the RA domain (Val211Ala), and they abolished the suppression activity of RASSF1A.
However, from this study it is not possible to conclude if both mutations are important or if only one of them, located either in DAG binding or RA domain, is critical for the loss of growth inhibitory activity. Still mutRASSF1A was not as effective as wild-type RASSF1A and RASSF1C in KRC/Y cells. Most likely, these two missense mutations did not completely inactivate the suppressive function and partially this function can be restored. As mutRASSF1A showed almost complete absence of growth inhibition in LNCaP prostate cells, we could suggest that the degree of its inactivation is dependent on other proteins and appears to be tissue specific. This remarkably reminds of the situation with RASSF1C that could be regarded in some sense as a RASSF1A protein lacking the protein kinase C1 homology (DAG) domain. Isolation of RASSF1A clones containing mutations in these domains, from tumor biopsies, could help to solve this problem.
As it was pointed in the Introduction section one of the most important issues in our study was to check the effect of RASSF1C in conditions close to physiologically normal. That is why we performed quantitative real time PCR with ABI Prism 7700 Sequence Detector (see Materials and methods) with probes specific only to RASSF1C. Removal of doxycycline in vitro increased transcription of ectopic RASSF1C 30-to 50-fold (depending on a particular cell clone). These experiments also showed that in the repressed state in vitro expression of RASSF1C in RC1 and RC5 clones was almost the same as in KRC/Y (difference less than 10%). However, in the activated state expression of ectopic RASSF1C in these clones achieved 60% of RASSF1C expression in normal kidney cells (data not shown).
The results of the present study demonstrated that RASSF1C efficiently blocked proliferation by inducing cell cycle arrest in KRC/Y cells. However, more experiments are needed to prove that RASSF1C may induce (or block) apoptosis because in adherent cells apoptosis sometimes could be very similar to other cell death processes, for example, necrosis.
We do not think that RASSF1 proteins are RAS effectors, to the contrary we hypothesize that RASSF1 proteins bind/sequester RAS, and thereby control the amount of RAS available for signal transduction. Similarly, the DAG domain may sequester the corresponding second messengers involved in RAS signaling networks. Therefore, inactivation or loss of RASSF1 would result in local 'overexpression' of RAS, which would in turn, drive malignant proliferation and block apoptosis. The multiplicity of the RASSF1 genes would be necessary to control multiple RAS genes that can signal from different cell compartments (Hingorani and Tuveson, 2003) .
Finally, our experiments confirmed that RASSF1A plays an important role as a tumor suppressor gene. At the same time, our study demonstrated that RASSF1C exhibits all the main TSG functions, such as growth inhibition in vitro and in vivo, and mutations or loss of expression in growing tumors (see Table 2 ). We suggest that different forms of RASSF1 genes could have tissue specific effects, and RASSF1C and RASSF1A may be important for the development of various, but different, types of malignancies.
Materials and methods

Cell line and general methods
All molecular, cell biology and microbiology procedures were performed as described previously (Zabarovsky et al., 1990; Li et al., 1999; Protopopov et al., 2002) .
Construction of pETE vector and U2020, KRC/Y and LNCaP cell lines producing tetracycline trans-activator tTA were described in Protopopov et al. (2002) .
Transfection, positive clone selection and Northern blotting RASSF1A, mutRASSF1A and RASSF1C were inserted into pETE digested by NheI and blunted with Klenow enzyme. pETE-RASSF1A, pETE-mutRASSF1A and pETE-RASSF1C recombinants were confirmed by sequencing on ABI310 Sequencer (Applied Biosystems, Foster City, USA) according to the manufacturer's protocol.
Plasmid DNAs were purified using R.E.A.L. Prep kit (Qiagen, Valencia, CA, USA). Transfections were performed using LipofectAMINE PLUS Reagent (Life Technologies, Rockville, MD, USA), according to the manufacturer's protocol.
After transfection, cells were selected with 200 U/ml hygromycin and 200 ng/ml doxycycline for 4 weeks.
PCR positive clones from each recombinant were grown in Iscove's cell culture medium supplemented with 10% heatinactivated FBS, 100 mg/ml penicillin, 100 mg/ml streptomycin, 200 U/ml hygromycin and 200 ng/ml doxycycline. Each clone was divided into two parallel flasks, in one of them cells were grown without doxycycline. After 1 week, 10 6 cells were collected and total RNA was isolated with Trizol s reagent (Life Technologies, Rockville, MD, USA).
Northern blotting and hybridization were performed as described before (Li et al., 1999) . RASSF1A, mutRASSF1A and RASSF1C probes were purified using electrophoresis and the Jetquick Gel Purification kit (Saveen, Germany). The probes were labeled with a-P 32 dCTP by random labeling. All growth inhibition experiments in vivo and in vitro were done as described previously (Li et al., 1999; Dreijerink et al., 2001; Kuzmin et al., 2002; Protopopov et al., 2002) .
FACS analysis
SKOV/p53, KRC/Y with the pETE, KRC/Y with the RASSF1C, clone RC1 (all without doxycycline) and KRC/Y with the RASSF1C, clone RC1 (with doxycycline) cells were grown in Iscoves's medium, 10 6 cells were collected, washed with PBS and centrifuged at 200 g for 5 min. The cell pellet was suspended in 100 ml PBS and fixed in cold 70% (vol/vol) ethanol by adding in ice 900 ml of cold (À201C) ethanol. After incubation on ice for 30 min, cells were concentrated by centrifugation, ethanol was removed and cells were suspended in 1.5 ml PBS at room temperature for 10 min. Then sample was centrifuged at 200 g for 5 min. Cell pellet suspended in 1 ml of DNA staining solution (10 ml PBS containing 500 mg propidium iodide and 2 mg RNaseA) was incubated for 30 min at room temperature in the dark. Finally, cells were subjected to fluoresence-activated cell sorting (FACS) that was performed by FACScan. In total, 10 000 cells were collected for each assay, and analysed by CellQuest software (Becton Dickinson).
Quantitative real-time PCR
ABI Prism s Model 7700 Sequence Detector (Applied Biosystems) and SYBR s Green JumpStartt Taq ReadyMixt kit (Sigma, Saint Louis, MO, USA) were used in this study. The following primer sequences specific for RASSF1C transcript were designed:
F1C-F-Q 5 0 -GGCTACGGACGCGCAGGACT-3 0 and F1C-R-Q 5 0 -AGTAGCCACTGCTCGTCGTGCTGCT-3. Experiments were performed according to the manufacturer's protocol.
Total RNA isolated from RC1 and RC5 clones (grown in the presence and without doxycycline) as well as from KRC/Y cells and normal kidney (two samples), ovary (three samples) and breast (two samples) was used in the experiments.
PCR reactions were carried out in triplicate. Comparative C T method (DDC T method) was used for quantification (Senchenko et al., 2003) . The parameter C T (threshold cycle) is defined as the cycle number required for dye fluorescence to become higher than background fluorescence level. The method is based on the inverse exponential relationship that exists between initial quantity (copy number) of target sequence copies in the reactions and corresponding C T determinations -the higher the starting copy number of RNA target, the less C T value. This method was used to determine mRNA copy number for RASSF1C in RC1, RC5 and KRC/Y cells relative to the normal RNA from different normal samples and to an endogenous control sequence -GAPDH. Data were analysed using ABI Prism s 7700 Sequence Detection System software (version 1.7). RASSF1C was well expressed in all normal samples; however, difference in the level of expression did not differ more than 1.5-fold in different tissues.
